Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Natural Food formulation for the prevention and treatment the Obesity and Metabolic Syndrome obtained with herbal extracts

Descripción del proyecto

Un buen mordisco al síndrome metabólico

El síndrome metabólico (SM) afecta a más de una cuarta parte de la población mundial y puede provocar varias afecciones graves, como ictus, cáncer, diabetes, enfermedad de Alzheimer y cardiopatías. La obesidad visceral es un síntoma fundamental y contribuye a la resistencia a la insulina, que es una de las principales causas del SM. El equipo del proyecto INNOPREFAT, financiado con fondos europeos, pretende desarrollar una solución natural para combatir el síndrome metabólico mediante la creación de una fórmula alimentaria denominada MetabolAid®. La reputada empresa española Monteloeder elaborará este producto a partir de extractos de hierbas. MetabolAid® ha sido diseñado para prevenir y tratar la obesidad y el SM mediante una fórmula sinérgica única, pruebas científicas, eficacia y una cadena de suministro transparente.

Objetivo

Monteloeder is a global developer, manufacturer and distributor of ingredients and formulations for the nutrition and cosmetics industry. It is committed to identifying and developing safe and effective ingredients derived from natural plants that deliver measureable benefits to consumers. Founded in 1996, Monteloeder today has sales in more than 38 countries and operates offices in Europe, US and Asia.

INNOPREFAT is the result of a long process led by Monteloeder to discover a natural solution to address one of the major epidemics of our time: Metabolic Syndrome (MetS). MetS can lead to serious diseases and conditions, including diabetes type-2, stroke, Alzheimer’s, cancer and heart disease. It affects more than 25% of the world’s population and represents a major and escalating global public health problem and clinical challenge. In Europe, about 8-18% of total adult healthcare expenditure is metabolic syndrome related.

The Business Model and the solution (MetabolAid®) are built around three dimensions: 1. A superior quality product based on a synergistic blend of two herbal extracts, which is supported by an extensive and rigorous scientific programme that demonstrates its effectiveness in improving MetS, as well as its safety and its economic viability. 2. A fully traceable, transparent and efficient supply chain, which guarantees that the product is natural, sustainably produced, completely safe and that it can be included in the main food matrices. 3. Global marketing approach includes a novel and original strategy: we will support our B2B clients with mobile phone health technology to manage end-consumer’s experience with the product and improve their levels of compliance, which in turn will enhance efficacy.

Monteloeder believes that those are the dimensions that will determine how ingredients must be designed, developed, produced and marketed to address the big changes in consumer preferences that are already taking place in the market.

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-2-2016-2017

Régimen de financiación

SME-2 - SME instrument phase 2

Coordinador

MONTELOEDER SL
Aportación neta de la UEn
€ 1 038 889,78
Dirección
CALLE MIGUEL SERVET 16 NAVE 17 PARQUE INSUTRIAL ELCHE
03203 Elche
España

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Este Comunitat Valenciana Alicante/Alacant
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 1 484 128,25